Navigation Links
Mayo Clinic reports possible new therapy for patients with platinum-resistant ovarian cancer
Date:10/23/2007

SAN FRANCISCO -- Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.

Findings from this Phase 2 Consortium (P2C) clinical trial were presented by the studys primary investigator, Keith Bible, M.D., Ph.D., at the Molecular Targets and Cancer Therapeutics International Conference, a jointly-sponsored symposium of the American Association for Cancer Research, National Cancer Institute and the European Organization for Research and Treatment of Cancer.

We are encouraged by the interim results of this trial, says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. Platinum-resistant ovarian cancer responds poorly to traditional therapies, and weve been working toward developing more effective treatments for this disease. This combination looks very promising.

More than 22,400 women in the United States will be diagnosed with ovarian cancer this year, according to the American Cancer Society, and nearly 15,300 women will die from it. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents).

In this study, the researchers evaluated a combination therapy using flavopiridol (an investigational anti-cancer agent that also boosts the effects of other therapeutics including cisplatin) with cisplatin (a platinum compound) for women with platinum-resistant ovarian or primary peritoneal (lining of the abdominal cavity) cancers. The researchers found in earlier preclinical studies that flavopiridol significantly boosts the anti-cancer effects of cisplatin, and later conducted a Phase I clinical trial to pilot the combination in patients (KC Bible et al, C
'/>"/>

Contact: Amy Tieder
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Scientists plan human cloning clinic in the United States
2. How do patients benefit of clinical trials
3. Magnetic resonance angiography in clinical medicine
4. Clinical trials need to be more frank
5. AEternas acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy
6. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
7. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
8. Clinical Comparisons Between ADHD Drugs Are Less
9. Specialized Clinics For Manipurs AIDS Patients
10. Outsourcing clinical trials to India
11. Erectile dysfunction: an early warning sign of clinically silent coronary artery disease?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...ple adjustments also save money, since side effect... , MONDAY, Oct. 6 (HealthDay News) -- Simple ch...uce the side effects children suffer while on opia...e study, a yearlong collaboration between 14 U.S. ...ease in "harmful events" caused by the pain reliev...
(Date:10/6/2008)... LearnCDHC, a Web-based reso...consumer-directed healthcare (CDHC) options includ...sement Accounts (HRAs) and Flexible Spending Accou...ept Media, to offer enterprise level services in c...l to midsize business model. , ...
(Date:10/6/2008)...ob Brown, Starring as Football Hero and Leukemia V...ia & Lymphoma Society,s 2008 Light The Night(R) ..., N.Y., Oct. 6 /PRNewswire/ -- Ernie Davis, a 1960... to win the Heisman Trophy,is the subject of the ...ing,to theaters Friday, Oct. 10. Davis overcame se...
(Date:10/6/2008)... MONTEREY, Calif., Oct. 6 /PRNewswire/ -- Today, P...tem using eFlow Technology that uses single,dose a...r system. By,creating a proprietary, unit-dose amp...e Closed System using eFlow Technology meets an un...edication in the delivery device,simplifying fill...
Breaking Medicine News(10 mins):Health News:Hospital Fixes Cut Opiate Errors in Kids 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:Release of Universal Film The Express Draws Attention to Tragedy of Lives Cut Short by Blood Cancer 2Health News:PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference 2
... response to the global burden imposed by the wide...nical drug trials involving herbal medicines. //It... are afflicted with the disease. The initiative w...edies in the treatment of AIDS/HIV. About 14 natur...
...growing number of animal and human studies show th... unexpected changes in pain sensitivity, resulting...nse to painful// stimulation) and allodynia (abnor...inful stimulation). Interestingly, prev...
...ofessor Vittorio Demicheli an Italian epidemiologi...involving the use of Mumps, Measles and Rubella (M...e link between MMR vaccination and autism or bowel...ne shots in children’s may cause Autism. This revi...
...searchers say low levels of low density lipoprotei...afe for heart patients who are taking statins.// T...LDL cholesterol from over 200 milligrams/deciliter...o one knows whether such levels are safe. Dr. Chri...
Other Medicine News:Health News:Opioids And Abnormal Pain Perception 2Health News:MMR Vaccination not linked to Autism 2
(Date:10/6/2008)...ent of moderate to severe patients achieved endosc...doscopic remission at Week 10,in data from a 54-we...ege,of Gastroenterology (ACG) Annual Scientific Me...today presented data from a,large, prospective stu...,disease (CD) with a biologic compound. The data p...
(Date:10/6/2008)...- Dendreon Corporation (Nas...ay, October 6, 2008 at 9:00 AM,ET (6:00 AM PT) to ...IMPACT,(IMmunotherapy for Prostate AdenoCarcinoma ... PROVENGE(R) (sipuleucel-T), the Company,s investi...atment of advanced prostate,cancer., Those int...
(Date:10/3/2008)..., New Jersey is the newest study site, PHILADELPH...,s Hospital,of Philadelphia today received a contr...ldren,s Study. Children,s Hospital will manage loc...in Burlington County, New,Jersey. The study is fun...igators anticipate approximately 1,000 families in...
(Date:10/2/2008)...rgent PC clinical success and expanded reimburseme...APOLIS, Oct. 2 /- Uroplasty...of the first patients in a new,randomized, control...Urgent,PC neuromodulation system for the treatment...rgency, urge incontinence and frequency of urinary...
Breaking Medicine Technology:CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2The Children's Hospital of Philadelphia Announces New Regional Participant in The National Children's Study 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 2Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 3Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial 4Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 1Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 2Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 3Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 4Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 5Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 6Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 7Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 8Baxter to Launch GARDian 28TM 29 a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients 156 9Biopure Gives Update on Malaysia Joint Venture Discussions 151 1Biopure Gives Update on Malaysia Joint Venture Discussions 151 2Biopure Gives Update on Malaysia Joint Venture Discussions 151 3Many Older Americans Have Active Sex Lives 151 1Many Older Americans Have Active Sex Lives 151 2Many Older Americans Have Active Sex Lives 151 3Many Older Americans Have Active Sex Lives 151 4FDA Approves First Anti Psychotic for Kids 148 1FDA Approves First Anti Psychotic for Kids 148 2FDA Approves First Anti Psychotic for Kids 148 3
...SHINGTON, June 20, 2007 /PRNewswire-USNewswire/ --...n issued the following,statement today after Presi... by vetoing the Stem Cell Research Enhancement Act...ding for life-saving,embryonic stem cell research,...le and passed both the House and Senate with,bipar...
...FORD, England, 20 June 2007 - VASTox plc (AIM: VOX...hat it has been awarded a,grant of £400,000 ...) under the SMARTCymru scheme. The grant,which r...evelopment,work undertaken at VASTox’s Abery...ique skills and expertise of its scientists,based ...
Other Medicine Technology:Dean: President Bush Has Turned His Back on the American People 2Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 2Vastox Awarded £400,000 Grant to Support R&D at,Carbohydrate Chemistry Facility 3
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
...es is a national reference laboratory and a worldw...evelopment. ARUP offers an extensive test menu of ...l and anatomic pathology. Owned by the University ...han half of the nation's university teaching hospi...
Medicine Products: